Arich Enterprise Co (ROCO:4173) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4173 Arich Enterprise Co Ltd ROCO:4173
70 GF Score
Price NT$17.40
GF Value NT$28.23
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Arich Enterprise Co Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:4173
70GF Score
Arich Enterprise Co Ltd ROCO:4173
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arich Enterprise Co (ROCO:4173) Overvalued in 2026?

Based on GuruFocus' analysis, Arich Enterprise Co stock appears to be undervalued. The current stock price of NT$17.40 is trading 38.4% below its estimated GF Value™ of NT$28.23. GuruFocus considers Arich Enterprise Co to be Possible Value Trap.

Key valuation signals for ROCO:4173:

  • Cash Payments:
  • GF Value™: NT$28.23 vs. price of NT$17.40 (38.4% below fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4173 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arich Enterprise Co Business Description

Address No.880, Zhongzheng Road, 14th Floor-5, Zhonghe District, Taipei, TWN, 235601
Arich Enterprise Co Ltd is a Taiwan-based pharmaceutical sales and logistics company. It provides medical sales promotion, marketing, and distribution services for pharmaceutical and healthcare products on behalf of manufacturers, rather than primarily developing its own drugs. Its customer base spans medical centers, regional and district hospitals, general practitioners, and key accounts such as chain stores, hypermarkets, drug stores, and wholesalers. The company's product portfolio includes medications such as Actos, Aftach, Cytotec, Gaster, Prometin, Hicee, Lederscon, Alinamin, Nacid, Setoral, and Sibutil, covering therapeutic areas including gastroenterology, diabetes, and neurology. Revenue is generated mainly through sales promotion commissions and product distribution margins across Taiwan's hospital and retail pharmacy channels.
70GF Score

Get the complete analysis for ROCO:4173

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.40
Price
NT$28.23
GF Value